Changes in lipoprotein(a) levels measured by six kit methods during growth hormone treatment of growth hormone-deficient adults.
Wieringa, Gilbert E Toogood, Andy Ryder, W David J Anderson, John Mackness, M Shalet, Stephen M
Wieringa, Gilbert E
Toogood, Andy
Ryder, W David J
Anderson, John
Mackness, M
Shalet, Stephen M
Citations
Altmetric:
Abstract
Lipoprotein(a) [Lp(a)], an independent risk factor for cardiovascular disease, has previously been reported to increase, decrease or show no change in growth hormone (GH)-deficient individuals receiving GH replacement. To assess whether these inconsistencies could be attributed to differences in immunoassay methods, Lp(a) was measured by six commercial kits at 0, 3, 6 and 9 months in nine GH-deficient individuals (median age 68.3 years, six male) during 9 months GH therapy. There was a significant rise in Lp(a) with the INCStar immunoturbidimetric (IT) method and the Mercodia enzyme linked immunosorbent assay (ELISA) (P
Description
Date
2000-02
Publisher
Collections
Keywords
Type
Article
Citation
Changes in lipoprotein(a) levels measured by six kit methods during growth hormone treatment of growth hormone-deficient adults. 2000, 10 (1):14-9 Growth Horm. IGF Res.